Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-04 03:51
摘要：
KRAS mutations are prevalent in various cancers and play a crucial role in immune suppression and tumor progression. The article reviews how these mutations remodel the immune microenvironment and metabolic pathways, leading to challenges in treatment. It highlights ongoing clinical trials for targeted therapies against KRAS mutations, suggesting significant potential for investment in this area of oncology.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
1.0分+1.0分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
KRAS mutations significantly affect the immune response of tumors.
Innovative combination therapies targeting KRAS are emerging.
The article discusses the metabolic pathways influenced by KRAS mutations.
真实性检查
否
AI评分总结
KRAS mutations are prevalent in various cancers and play a crucial role in immune suppression and tumor progression. The article reviews how these mutations remodel the immune microenvironment and metabolic pathways, leading to challenges in treatment. It highlights ongoing clinical trials for targeted therapies against KRAS mutations, suggesting significant potential for investment in this area of oncology.